Dr. Ian Schnadig shares Phase 3 trial results at ASCO

Ian Schnadig, MD discusses the Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC).